Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The azalide antibacterial agent azithromycin is a semisynthetic acid-stable erythromycin derivative with an expanded spectrum of activity and improved tissue pharmacokinetic characteristics relative to erythromycin. The drug is noted for its activity against some Gram-negative organisms associated with respiratory tract infections, particularly Haemophilus influenzae. Azithromycin has similar activity to other macrolides against Streptococcus pneumoniae and Moraxella catarrhalis, and is active against atypical pathogens such as Legionella pneumophila, Chlamydia pneumoniae and Mycoplasma pneumoniae.
Once-daily administration of azithromycin is made possible by the long elimination half-life of the drug from tissue. Azithromycin is rapidly and highly concentrated in a number of cell types after absorption, including leucocytes, monocytes and macrophages. It undergoes extensive distribution into tissue, from where it is subsequently eliminated slowly.
A 3-day oral regimen of once-daily azithromycin has been shown to be as effective as 5- to 10-day courses of other more frequently administered antibacterial agents [such as erythromycin, amoxicillin-clavulanic acid and Phenoxymethylpenicillin (penicillin V)] in patients with acute exacerbations of chronic bronchitis, pneumonia, sinusitis, pharyngitis, tonsillitis and otitis media. Adverse effects of azithromycin are mainly gastrointestinal in nature and occur less frequently than with erythromycin.
Azithromycin is likely to prove most useful as a 3-day regimen in the empirical management of respiratory tract infections in the community. Its ease of administration and 3-day duration of therapy, together with its good gastrointestinal tolerability, should optimise patient compliance (the highest level of which is achieved with once-daily regimens). Azithromycin is also likely to be useful in the hospital setting, particularly for outpatients and for those unable to tolerate erythromycin.
Overview of in Vitro Antibacterial Activity
Azithromycin has a similar spectrum of activity to erythromycin but is particularly noted for its activity against a number of Gram-negative organisms. On the basis of in vitro data, azithromycin is more active than erythromycin, clarithromycin and roxithromycin against Haemophilus influenzae. Azithromycin shows similar activity to erythromycin, clarithromycin and roxithromycin against Moraxella catarrhalis (with good activity against β-lactamase-positive strains of this organism) and Streptococcus pneumoniae.
Clinical isolates of Legionella pneumophila and Chlamydia pneumoniae are susceptible to azithromycin. In particular, the drug is very active against Mycoplasma pneumoniae, with in vitro data from 1 study showing the mean minimum drug concentration required to inhibit 90% of strains (MIC90) for erythromycin, clarithromycin and roxithromycin to be at least 32.5 times greater than that for azithromycin.
Erythromycin-susceptible strains of Staphylococcus aureus and most streptococci are susceptible to azithromycin, and the drug has shown good activity against S. pyogenes in studies conducted in vitro. Streptococcal and staphylococcal species that are resistant to erythromycin are also likely to be resistant to azithromycin, as are methicillin-resistant strains of S. aureus.
Overview of Pharmacokinetic Properties
Oral administration of azithromycin 500mg produces a peak serum concentration of approximately 0.4 to 0.45 mg/L after 2.5 hours. The drug is rapidly and highly concentrated in white blood cells and macrophages, undergoes extensive tissue distribution and achieves high concentrations in pulmonary and tonsillar tissue.
Azithromycin is largely eliminated unchanged via the faecal route, although some hepatic metabolism does occur. Polyphasic elimination reflects the initial rapid distribution of the drug into tissue and its subsequent slow elimination therefrom. A mean terminal serum elimination half-life of 57 hours has been reported for azithromycin.
Therapeutic Efficacy of 3-Day Azithromycin in Respiratory Tract Infections
Results of comparative trials have shown similar clinical efficacy for 3-day regimens of azithromycin and 5- to 10-day courses of other antibacterial drugs, including amoxicillin-clavulanic acid, erythromycin, clarithromycin, roxithromycin and josamycin in patients with acute bronchitis, acute exacerbations of chronic bronchitis or pneumonia. Combined rates of clinical cure and clinical improvement (cure plus improvement) 10 to 14 days after the start of therapy were similar for azithromycin and amoxicillin-clavulanic acid in patients with infections caused mainly by S. pneumoniae, H. influenzae or M. catarrhalis. Bacteriological efficacy (based on the eradication or presumed eradication of infecting pathogens) varied between trials but was similar for azithromycin and the comparator agent in most studies.
Azithromycin administered once a day for 3 days was as effective as a 5-day regimen of the drug in 84 patients with pneumonia caused by atypical pathogens such as M. pneumoniae, C. psittaci or Coxiella burnetii. Most studies in lower respiratory tract infections involved adults, but some paediatric data are also available.
Clinical cure plus improvement rates of 93 to 100% were reported in studies of patients (including children) with upper respiratory tract infections (acute pharyngitis, tonsillitis, sinusitis or otitis media) who received 3-day courses of azithromycin. Similar cure plus improvement rates were observed after 7- to 10-day courses of erythromycin, clarithromycin, roxithromycin, Phenoxymethylpenicillin (penicillin V), amoxicillin (with or without clavulanic acid) and cefaclor in these trials.
Pooled tolerability data from phase II and III studies of 3995 patients aged from 2 to 94 years showed orally administered azithromycin to be associated predominantly with gastrointestinal and central and peripheral nervous system adverse events (most of the patients who were included had received a total dose of azithromycin 1500mg over 5 days). The gastrointestinal tolerability of azithromycin was superior to that of erythromycin in this analysis.
A further analysis of tolerability data from clinical trials which involved 1129 children and young adults, 606 of whom received azithromycin (544 received the 3-day regimen), showed an incidence of adverse events of 7.6% for azithromycin and 13.8% overall for other antibacterial drugs, including amoxicillin, Phenoxymethylpenicillin, erythromycin and flucloxacillin. Gastrointestinal adverse events were reported significantly less frequently by azithromycin recipients than by those receiving other drugs.
Pooled data from 43 studies in 4499 children (aged 6 months to 16 years) who received 3-day azithromycin showed similar overall tolerability for azithromycin and a number of penicillins, cephalosporins and macrolides.
Azithromycin has not been associated with any clinically significant biochemical or haematological abnormalities.
Azithromycin does not interact with the hepatic cytochrome P450 system and is not associated with the pharmacokinetic drug interactions seen with erythromycin and other macrolides. The drug does not appear to affect metabolism of theophylline, carbamazepine, midazolam or terfenadine. Furthermore, the anticoagulant effect of a single 15mg dose of warfarin was not affected by concurrent therapy with azithromycin.
Serum cyclosporin and digoxin concentrations should be monitored when either of these 2 agents is given during treatment with azithromycin. Concurrent administration of the drug with ergot derivatives should be avoided.
Dosage and Administration
An oral dose of azithromycin 500mg should be given once daily for 3 days in upper and lower respiratory tract infections. Children aged over 6 months who weigh less than 45kg should receive 10 mg/kg once daily for 3 days. No dosage recommendations have been made for children aged under 6 months. Although it is recommended that azithromycin capsules are taken 1 hour before or 2 hours after food, recent data indicate that this is not necessary with the oral suspension and a novel tablet formulation of the drug.
- Ballow, C.H., Amsden, G.W. (1992) Azithromycin: the first azalide antibiotic. Ann Pharmacother 26: pp. 1253-61
- Piscitelli, S.C., Danziger, L.H., Rodvold, K.A. (1992) Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 11: pp. 137-52
- Peters, D.H., Friedel, H.A., McTavish, D. (1992) Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44: pp. 750-99
- Fass, R.J. (1993) In vitro activity of Bay y 3118, a new quinolone. Anti-microb Agents Chemother 37: pp. 2348-57
- Felmingham, D., Robbins, M.J., Sanghrajka, M. (1991) The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res 17: pp. 91-9
- Hussain Qadri, S.M., Ueno, Y., Tulio, D. (1994) In vitro activity of azithromycin: a long-acting azalide. Ann Saudi Med 14: pp. 122-4
- Maskell, J.P., Sefton, A.M., Williams, J.D. (1990) Comparative in-vitro activity of azithromycin and erythromycin against Grampositive cocci, Haemophilus influenzae and anaerobes. J Antimicrob Chemother 25: pp. 19-24
- Neu, H.C., Chin, N.-x., Gu, J.-w. (1992) The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP54476, alone and in combination. J Antimicrob Chemother 30: pp. 83-94
- Sefton, A.M., Maskell, J.P., Yong, F.J. (1988) Comparative in vitro activity of A-56268. Eur J Clin Microbiol Infect Dis 7: pp. 798-802
- Barry, A.L., Fuchs, P.C. (1995) In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 39: pp. 238-40
- Barry, A.L., Thornsberry, C., Jones, R.N. (1987) In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin and clindamycin. Antimicrob Agents Chemother 31: pp. 343-5
- Barry, A.L. (1992) In vitro potency of nine orally administered antimicrobial agents against three respiratory tract pathogens. Eur J Clin Microbiol Infect Dis 11: pp. 867-9
- Rolston, K.V., Ho, D.H., LeBlanc, B. (1990) Comparative in vitro activity of the new erythromycin derivative dirithromycin against Gram-positive bacteria isolated from cancer patients. Eur J Clin Microbiol Infect Dis 9: pp. 30-3
- Bauernfeind, A. (1993) In-vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother 31: pp. 39-49
- Urbášková, P., Trupl, J., Hupková, H. (1995) In vitro susceptibility of penicillin-susceptible and resistant pneumococci from central Europe to penicillin G, CP99.219, ciprofloxacin, Sparfloxacin, clindamycin, Cefpodoxime, erythromycin and azithromycin [abstract no. 306].
- Prado, V., Romero, J., Herrera, N. (1993) Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains isolated in Chile between 1990 and 1992 [in Spanish]. Rev Med Chil 121: pp. 1128-34
- Goldstein, F.W., Emirian, M.F., Coutrot, J.F. (1990) Bacteriostatic and bactericidal activity of azithromycin against Haemophilus influenzae. J Antimicrob Chemother 25: pp. 25-8
- Hardy, D.J., Hensey, D.M., Beyer, J.M. (1988) Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 32: pp. 1710-9
- Bergeron, M.G., Lavoie, G.Y., Boucher, F.D.W. (1987) Comparative bactericidal activity of Cefixime, carumonam, enoxacin and roxithromycin with those of other antibiotics against resistant Haemophilus influenzae including β-lactam tolerant strains. J Antimicrob Chemother 20: pp. 663-9
- Chen, S.C.A., Paul, M.L., Gilbert, G.L. (1993) Susceptibility of Legionella species to antimicrobial agents. Pathology 25: pp. 180-3
- Johnson, D.M., Erwin, M.E., Barrett, M.S. (1992) Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis 11: pp. 751-5
- Chardon, H., Bellon, O., Bourgeois, F. (1989) Comparative in vitro activity of five macrolides against 190 strains of Branhamella catarrhalis [in French. Pathol Biol 37: pp. 382-5
- Spencer, R.C., Wheat, P.F. (1992) In vitro activity of roxithromycin against Moraxella catarrhalis. Diagn Microbiol Infect Dis 15: pp. 63S-5S
- Hammerschlag, M.R., Qumei, K.K., Roblin, P.M. (1992) In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 36: pp. 1573-4
- Ishida, K., Kaku, M., Irifune, K. (1994) In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 38: pp. 790-8
- Renaudin, H., Bébéar, C. (1990) Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomeflox-acin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 9: pp. 838-41
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fifth informational supplement. Pennsylvania: NCCLS, 1994. NCCLS document M100-S5
- Jones, R.N. Disk diffusion susceptibility testing of macrolides: the interpretive criteria. In: Bryskier, A.J., Butzler, J.-P., Neu, H.C. eds. (1993) Macrolides: chemistry, pharmacology and clinical uses. Arnette Blackwell, Paris, pp. 209-15
- Farmer, S., Li, Z., Hancock, R.E.W. (1992) Influence of outer membrane mutations on susceptibility of Escherichia coli to the dibasic macrolide azithromycin. J Antimicrob Chemother 29: pp. 27-33
- Neu, H.C. (1995) Otitis media: antibiotic resistance of causative pathogens and treatment alternatives. Pediatr Infect Dis J 14: pp. 51-6
- Fox, R.A. (1993) Treatment recommendations for respiratory tract infections associated with aging. Drugs Aging 3: pp. 40-8
- Peters, D.H., Clissold, S.P. (1992) Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44: pp. 117-64
- Neal, T.J., O’Donoghue, M.A.T., Ridgway, E.J. (1992) In-vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 30: pp. 39-46
- Kanatani, M.S., Guglielmo, B.J. (1994) The new macrolides: azithromycin and clarithromycin. West J Med 160: pp. 31-7
- Daikos, G.K. (1991) Continuous versus discontinuous antibiotic therapy: the role of the post-antibiotic effect and other factors. J Antimicrob Chemother 27: pp. 157-60
- Debbia, E.A., Molinari, G., Paglia, P. (1990) Post-antibiotic effect of azithromycin on respiratory tract pathogens. Drugs Exp Clin Res 16: pp. 615-9
- Odenholt-Tornqvist, I., Löwdin, E., Cars, O. (1995) Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 39: pp. 221-6
- Foulds, G., Shepard, R.M., Johnson, R.B. (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25: pp. 73-82
- Cooper, M.A., Nye, K., Andrews, J.M. (1990) The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 26: pp. 533-8
- Baldwin, D.R., Ashby, J.R., Andrews, J.M. (1990) Pulmonary disposition of azithromycin following a single 500 mg oral dose [abstract]. Thorax 45: pp. 324P
- Johnson, R.B. (1991) The role of azalide antibiotics in the treatment of chlamydia. Am J Obstet Gynecol 164: pp. 1794-6
- Shepard, R.M., Weidler, D.J., Garg, D.C. (1987) Human pharmacokinetics of azithromycin (CP-62,993/XZ-450), a new macrolide with an extended half-life and high tissue penetration.
- Bergogne-Bérézin, E. (1993) Tissue distribution of dirithromycin: comparison of erythromycin. J Antimicrob Chemother 31: pp. 77-87
- Periti, P., Mazzei, T., Mini, E. (1992) Pharmacokinetic drug interactions of macrolides [published erratum appears in Clin Pharmacokinet 1993 Jan; 24 (1): 70J. Clin Pharmacokinet 23: pp. 106-31
- Yakatan, G.J., Rasmussen, C.E., Feis, P.J. (1985) Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses. J Clin Pharmacol 25: pp. 36-42
- Rutland, J., Berend, N., Marlin, G.E. (1979) The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol 8: pp. 343-7
- Bahal, N., Nahata, M.C. (1992) The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 26: pp. 46-55
- Paulsen, O. (1991) Roxithromycin — a macrolide with improved pharmacokinetic properties. Drugs Today 27: pp. 193-222
- Fiese, E.F., Steffen, S.H. (1990) Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 25: pp. 39-47
- Wollmer, P., Rhodes, C.G., Pike, V.W. (1982) Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron tomography. Lancet 2: pp. 1361-4
- Morris, D.L., Souza, A., Jones, J.A. (1991) High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur J Clin Microbiol Infect Dis 10: pp. 859-61
- Cazzola, M., Siniscalchi, C., Vinciguerra, A. (1994) Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. Int J Clin Pharmacol Ther 32: pp. 88-91
- Baldwin, D.R., Wise, R., Andrews, J.M. (1990) Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 3: pp. 886-90
- Karma, P., Pukander, J., Penttila, M. (1991) Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis 10: pp. 856-9
- Foulds, G., Chan, K.H., Johnson, J.T. (1991) Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 10: pp. 853-6
- Gladue, R.P., Bright, G.M., Isaacson, R.E. (1989) In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33: pp. 277-82
- Lode, H. (1991) The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 10: pp. 807-12
- Lalak, N.J., Morris, D.L. (1993) Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 25: pp. 370-4
- Mazzei, T., Surrenti, C., Novelli, A. (1993) Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 31: pp. 57-63
- Havlir, D.V. (1994) Mycobacterium avium complex: advances in therapy. Eur J Clin Microbiol Infect Dis 13: pp. 915-24
- Amaya-Tapia, G., Aguirre-Avalos, G. (1993) Andrade-Villanueva J, et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J Antimicrob Chemother 31: pp. 129-35
- Rodriguez-Solares, A., Pérez-Gutiérrez, F., Prosperi, J. (1993) A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 31: pp. 103-9
- Lo-Bue, A.M., Sammartino, R., Chisari, G. (1993) Efficacy of azithromycin compared with spiramycin in the treatment of odontogenic infections. J Antimicrob Chemother 31: pp. 119-27
- Mohs, E., Rodriguez-Solares, A., Rivas, E. (1993) A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media. J Antimicrob Chemother 31: pp. 73-9
- Bradbury, F. (1993) Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 31: pp. 153-62
- Morandini, G., Perduca, M., Zannini, G. (1993) Clinical efficacy of azithromycin in lower respiratory tract infections. J Chemother 5: pp. 32-6
- Principi, N. (1995) Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 14: pp. 669-76
- Marchant, C.D., Carlin, S.A., Johnson, C.E. (1992) Measuring the comparative efficacy of antibacterial agents for acute otitis media: the ‘Pollyanna phenomenon. J Pediatr 120: pp. 72-7
- Gwaltney, J.M. Acute bronchitis. In: Mandell, G.L., Gordon Douglas, R., Bennett, J.E. eds. (1990) Principles and practice of infectious diseases. Churchill Livingstone, New York, pp. 529-31
- Reynolds, H.Y. Chronic bronchitis and acute infectious exacerbations. In: Mandell, G.L., Gordon Douglas, R., Bennett, J.E. eds. (1990) Principles and practice of infectious diseases. Churchill Livingstone, New York, pp. 531-5
- Donowitz, G.R., Mandell, G.L. Acute pneumonia. In: Mandell, G.L., Gordon Douglas, R., Bennett, J.E. eds. (1990) Principles and practice of infectious diseases. Churchill Livingstone, New York, pp. 540-55
- Franckart, G., Waelbroeck, A., Demol, P. (1995) Azithromycin vs erythromycin in the treatment of lower respiratory tract infections in children [abstract].
- Principi, N., Marchisio, P., Biasini, G. (1993) Azithromycin versus erythromycin in the treatment of paediatric community-acquired pneumonia. Eur J Clin Res 4: pp. 127-33
- Ronchetti, R., Blasi, F., Grossi, E. (1994) The role of azithromycin in treating children with community-acquired pneumonia. Curr Ther Res 55: pp. 965-70
- Beghi, G., Berni, F., Carratù, L. (1995) Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 7: pp. 146-52
- Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. J Antimicrob Chemother. In press
- Hoepelman, A.I.M., Sips, A.P., Helmond, J.L.M. (1993) A single-blind comparison of three-day azithromycin and ten-day coamoxiclav treatment of acute lower respiratory tract infections. J Antimicrob Chemother 31: pp. 147-52
- Hoepelman, I.M., Möllers, M.J., Schie, M.H. (1995) Azithromycin (A) tablets for 3 days versus 10 days Augmentin (Aug) in adults with lower respiratory tract infection [abstract no. 764].
- Zachariah J. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav for the treatment of adult patients with lower respiratory tract infections. J Antimicrob Chemother. In press
- Mertens, J.C.C., Barneveld, P.W.C., Asin, H.R.G. (1992) Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother 36: pp. 1456-9
- Laurent K. Efficacy, safety and toleration of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections. J Antimicrob Chemother. In press
- Rizzato, G., Montemurro, L., Fraioli, P. (1995) Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 8: pp. 398-402
- Schönwald, S., Barsic, B., Klinar, I. (1994) Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pnemonia. Scand J Infect Dis 26: pp. 706-10
- Gonzales, R., Sande, M. (1995) What will it take to stop physicians from prescribing antibiotics in acute bronchitis? [commentary. Lancet 345: pp. 665-6
- Schönwald, S., Skerk, V., Petricevic, I. (1991) Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis 10: pp. 877-80
- Pichichero, M.E. (1992) Therapeutic considerations for management of otitis media, sinusitis, and tonsillopharyngitis. Pediatr Asthma Allergy Immunol 6: pp. 167-74
- Pichichero, M.E. (1995) Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment [see comments]. Ann Emerg Med 25: pp. 390-403
- Bosatra, A., Tattoni, P., Podda, M. (1994) Study on effectiveness and tolerance to azithromycin v’s roxithromycin in the treatment of patients with upper respiratory tract infections [in Italian]. Clin Ter 144: pp. 27-30
- Schaad, U.B. (1993) Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother 31: pp. 81-8
- Daniel, R.R. (1993) Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 31: pp. 65-71
- Hamill, J. (1993) Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 31: pp. 89-94
- O’Doherty, B. (1995) Azithromycin versus penicillin V in the treatment of pediatric patients with acute pharyngitis/tonsillitis [abstract no. 1388].
- Müller, O. (1993) Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 31: pp. 137-46
- Müller O. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J Antimicrob Chemother. In press
- Weippl, G. (1993) Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 31: pp. 95-101
- O’Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. In press
- Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of paediatric patients with acute otitis media. J Antimicrob Chemother. In press
- Hopkins, S. (1991) Clinical toleration and safety of azithromycin. Am J Med 91: pp. 40-5
- Hopkins, S. (1993) Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 31: pp. 111-7
- Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother. In press
- George, J., Farrell, G.C. (1991) Role of human hepatic cytochromes P450 in drug metabolism and toxicity. Aust NZ J Med 21: pp. 356-62
- Rosenstiel, N.-A., Adam, D. (1995) Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 13: pp. 105-22
- Gardner, M.J., Coates, P.E., Hilligoss, D.M. (1992) Lack of effect of azithromycin on the pharmacokinetics of theophylline in man.
- Clauzel, A.M., Visier, S., Michel, F.B. (1990) Efficacy and safety of azithromycine in lower respiratory tract infections [abstract]. Eur Respir J 3: pp. 89
- Harris, S., Hilligoss, D.M., Colangelo, P.M. (1995) Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 58: pp. 310-5
- Rapeport, W.G., Dewland, P.M., Muirhead, D.C. (1992) Lack of an interaction between azithromycin and carbamazepine [abstract]. Br J Clin Pharmacol 33: pp. 55 IP
- Mattila, M.J., Vanakoski, J., Idänpään-Heikkilä, J.J. (1994) Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 47: pp. 49-52
- Zimmermann, T., Laufen, H., Yeates, R.A. (1995) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam [abstract no. 777].
- Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron 1995 May; 70: 130
- Zithromax. Walker, G. eds. (1994) ABPI Data Sheet Compendium 1994–95. Datapharm Publications Ltd., London, pp. 1285-6
- Foulds G, Luke DR, Teng R, et al. Food does not affect the bioavailability of azithromycin tablets, sachet, or suspension. J Antimicrob Chemother. In press
- Schentag, J.J. (1995) Antibiotic treatment of acute otitis media in children: dosing considerations. Pediatr Infect Dis J 14: pp. S30-33
- Ball, P., Tillotson, G., Wilson, R. (1995) Chemotherapy for chronic bronchitis: controversies. Presse Med 24: pp. 189-94
- Place in therapy of the newer macrolides: clarithromycin and azithromycin. Drug Ther Perspect 1993 Jan 25; 1 1: 5-7
- Cook, P.J., Honeybourne, D. (1995) Clinical aspects of Chlamydia pneumoniae infection. Presse Med 24: pp. 278-82
- Grayston, J.T. (1992) Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 15: pp. 757-63
- Feldman, J.A., DeTullio, P.L. (1994) Medication noncompliance: an issue to consider in the drug selection process. Hosp Formul 29: pp. 204-11
- Pfizer on Zithromax cost. Scrip Mag 1995 Jul 4 (2039): 23
- Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148: pp. 1418-26
- Eron, J.J.J., Burkle, W., Cohen, M.S. (1994) Managing pneumonia: defining the role of the new macrolide antibiotics. Hosp Formul 29: pp. 122-36
Volume 51, Issue 3 , pp 483-505
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors